Navigation Links
Micromet to Present at the Cowen Health Care Conference on March 17, 2009
Date:3/6/2009

safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made p
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... Gas Analyzer, and Gas Chromatograph Market by Type , ... Global Trends & Forecast to 2013 - 2020" ... analyzer is a process analytical instrument that provides chemical ... redefined the way by which companies carry out their ...
(Date:9/29/2014)... September 29, 2014 Transparency Market Research, ... - SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, ... Generic and by Delivery) - Global Industry Analysis, Size, ... that the global peptide therapeutics market was worth US$14.1 ... billion by 2018 at an 8.7% CAGR. , The ...
(Date:9/29/2014)... Sept. 29, 2014  Atlas Venture, an early stage ... technology innovation, today announced that Jason Rhodes , ... EPZM ), is joining the firm,s life sciences ... At Atlas, Rhodes will work closely with ... brings an accomplished record in company creation, deal making ...
(Date:9/29/2014)... 29, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... Winkley to Chairman of the Board of Directors ... will continue to serve as a Director on the ... Company.  "We are very pleased to ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... , QIAshredder spin columns are designed for simple and rapid homogenization , of cell and ... , , Format: , ... , , Sample source: ... plant cell or tissue lysates, white blood cell lysates, , ...
... , , , , This ... human cancer-related genes for functional genomics research using , RNAi. ... , , , , ... cancer researchers (see table below for a list of genes). Every siRNA has , ...
... Competent Cells for added , convenience, , , , , , , ... Included , Concentration , , , ... , , , ... 50 ng/l, , , Ligation Master ...
Cached Biology Technology:QIAshredder Homogenizer 2Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:9/29/2014)... popular culture, mathematics is often deemed inaccessible or esoteric. ... more important role in our daily lives and a ... ideas often behind the scenes. , UC Santa ... Mathematics and an assistant professor of mechanical engineering, often ... of his recent research published in the Proceedings ...
(Date:9/29/2014)... that a combination of a real-time feedback system together ... residence resulted in a reduction of 37% in energy ... 1360.49 kWh, which is equivalent to a reduction of ... , In contrast, another eight halls, exposed only ... resulted in saw a 3.5% reduction in energy consumption. ...
(Date:9/29/2014)... not normally considered capable of doing anything on their ... move through water. In the future, such moving droplets ... your own to be self-moving is a ... entities can be self-moving, report researchers from University of ... Czech Republic. , The researchers have made alcohol droplets ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Scientists make droplets move on their own 2
... Mellon University President Subra Suresh has been elected a ... the only current university president to be elected to ... is among the highest professional distinctions accorded to engineers, ... those who have made outstanding contributions to their fields. ...
... Medicine of the National Academies honored members Donald Berwick, R. ... today at the IOM,s 43rd annual meeting. ... member for distinguished service over an extended period. He ... Care in America, which produced the landmark reports To Err ...
... The Yangtze finless porpoise, which inhabits the high-traffic waters ... endangered, with only about 1,000 animals alive today. Scientists ... colleagues are using medical technology to shed new light ... waterway punctuated by constant shipping, dredging, and underwater construction. ...
Cached Biology News:Carnegie Mellon President Subra Suresh elected to Institute of Medicine 2Institute of Medicine honors members for outstanding service 2Institute of Medicine honors members for outstanding service 3Seeing in the dark 2Seeing in the dark 3
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Biology Products: